Clarity Pharmaceuticals Statistics
Total Valuation
Clarity Pharmaceuticals has a market cap or net worth of AUD 1.91 billion. The enterprise value is 1.78 billion.
Market Cap | 1.91B |
Enterprise Value | 1.78B |
Important Dates
The next estimated earnings date is Friday, November 29, 2024.
Earnings Date | Nov 29, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Clarity Pharmaceuticals has 320.21 million shares outstanding. The number of shares has increased by 5.22% in one year.
Current Share Class | n/a |
Shares Outstanding | 320.21M |
Shares Change (YoY) | +5.22% |
Shares Change (QoQ) | +8.57% |
Owned by Insiders (%) | 17.84% |
Owned by Institutions (%) | 12.51% |
Float | 224.03M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 141.72 |
PB Ratio | 12.72 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -41.94 |
EV / Sales | 154.27 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -40.58 |
Financial Position
The company has a current ratio of 19.05
Current Ratio | 19.05 |
Quick Ratio | 18.44 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -39.29% and return on invested capital (ROIC) is -25.99%.
Return on Equity (ROE) | -39.29% |
Return on Assets (ROA) | -24.19% |
Return on Capital (ROIC) | -25.99% |
Revenue Per Employee | 230,133 |
Profits Per Employee | -846,489 |
Employee Count | 50 |
Asset Turnover | 0.10 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +345.87% in the last 52 weeks. The beta is 1.58, so Clarity Pharmaceuticals's price volatility has been higher than the market average.
Beta (5Y) | 1.58 |
52-Week Price Change | +345.87% |
50-Day Moving Average | 7.23 |
200-Day Moving Average | 5.38 |
Relative Strength Index (RSI) | 32.96 |
Average Volume (20 Days) | 1,195,291 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Clarity Pharmaceuticals had revenue of AUD 11.51 million and -42.32 million in losses. Loss per share was -0.15.
Revenue | 11.51M |
Gross Profit | 11.51M |
Operating Income | -44.80M |
Pretax Income | -42.03M |
Net Income | -42.32M |
EBITDA | -44.65M |
EBIT | -44.80M |
Loss Per Share | -0.15 |
Balance Sheet
Cash & Cash Equivalents | 136.51M |
Total Debt | n/a |
Net Cash | 136.51M |
Net Cash Per Share | 0.43 |
Equity (Book Value) | 146.30M |
Book Value Per Share | 0.47 |
Working Capital | 145.97M |
Cash Flow
In the last 12 months, operating cash flow was -43.24 million and capital expenditures -504,005, giving a free cash flow of -43.74 million.
Operating Cash Flow | -43.24M |
Capital Expenditures | -504,005 |
Free Cash Flow | -43.74M |
FCF Per Share | -0.14 |
Margins
Gross Margin | 100.00% |
Operating Margin | -389.35% |
Pretax Margin | -365.26% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -380.14% |
Dividends & Yields
Clarity Pharmaceuticals does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -5.22% |
Shareholder Yield | -5.22% |
Earnings Yield | -2.60% |
FCF Yield | -2.29% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Clarity Pharmaceuticals has an Altman Z-Score of 43.45.
Altman Z-Score | 43.45 |
Piotroski F-Score | n/a |